John Mascarenhas, MD, hosts a panel of experts who discusses current strategies used to stratify risk patients with myelofibrosis and their preferences for sequencing therapy.
At an Around the Practice presentation hosted by CancerNetwork, experts discussed recent advancements in the treatment of patients with myelofibrosis. The panel was led by John Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and a member of the Tisch Cancer Institute at Mount Sinai in New York.
The expert panel also included Aaron Gerds, MD, MS, a physician at the Cleveland Clinic as well as assistant professor in the School of Medicine and member of the Developmental Therapeutics Program of Case Comprehensive Cancer Center at Case Western Reserve University in Cleveland, Ohio; Raajit Rampal, MD, PhD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center in New York; and Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms, chief of the Section for Myeloproliferative Neoplasms, and professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston.
Mascarenhas: Can you explain what myelofibrosis is? How do you distinguish between primary and secondary disease?
Gerd: The hallmark [of myelofibrosis] is scar tissue in the bone marrow, which is the common pathologic finding that we see. Mutations that occur in the JAK-STAT signaling pathway lead to this proliferation and growth and the ultimate scarring of tissue in the marrow. Over time, that scar tissue can lead to dysfunction in the hematopoietic process, and you see low blood counts in patients. As for primary vs secondary myelofibrosis, those words are tricky [because] primary myelofibrosis refers to [the] disease of bone marrow cancer. Secondary can mean either inflammatory scar tissue in the bone marrow vs a rheumatological disorder, for example, and it can also indicate myelofibrosis that has evolved out of a preexisting polycythemia vera (PV) or essential thrombocythemia (ET).
Mascarenhas: What are some examples of nonmyeloproliferative neoplasm [MPN] secondary myelofibrosis? In what other settings could you see a myelofibrotic marrow?
Rampal: Fibrosis in the marrow is nonspecific, in many cases. Can you see it in other myeloid diseases? The answer is yes. Rarely, you see it in MDS [myelodysplastic syndrome]. A rare MDS subtype [exists], known as MDS with fibrosis, but beyond hematologic cancers, you can certainly see it in autoimmune conditions.
Mascarenhas: How do signaling pathway mutations and genetic and epigenetic alterations contribute to the pathophysiology of myelofibrosis?Rampal: The hallmark of MPN pathogenesis [consists of] activations in the JAK-STAT pathway, which is a pathway that is involved in both inflammation and hematopoiesis. The disease is principally driven by unregulated JAK-STAT signaling. Other mutations can occur in the disease as well, and its very clear to us from both patient data and laboratory data that those mutations can alter the biology of the disease and, in many cases, advance it or cause it to be more aggressive. In addition, other pathways are activated by the JAK-STAT pathway, which we think plays a role in the pathogenesis of the disease. [Those mechanisms] are currently targets of inhibitors in clinical trials.
Mascarenhas: What are the biomarkers of interest?
Verstovsek: The prognostication in myelofibrosis has become complicated because we have identified multiple different biomarkers. Fifteen years ago, we started with the biomarkers that would be easy to understand, [such as] the number of white blood cells, blasts in the blood, or a clinical finding like symptoms or age. Since then, the other biomarkers we have identified [include] different driver mutations that activate the JAK-STAT pathway, like JAK2, CALR, or MPL mutations. [Patients who have] none of the 3 biomarkers are called triple negative, which we can test for by NGS [next-generation sequencing] panels in academic centers.
Mascarenhas: Are you doing tests like NGS in a serial fashion?
Verstovsek: We do repeat the testing automatically when clinical progression [occurs]. Ideally, [you would] test patients periodically, even when theyre stable, to predict a progression by acquisition of certain molecular abnormalities or cytogenetic abnormalities, but that is not a standard practice [because its] not feasible. This is [also] not being done because you cant do much [with that information]. You do something when things change clinically, so the information [would be] applicable to or [would] influence the management. Then, its justifiable to test.
In a polling question, the audience indicated that fatigue was the most common symptom they saw in their patients with myelofibrosis (poll question 1).
Mascarenhas: What drives fatigue in myelofibrosis?
Rampal: Often, we need to figure it out. For example, if a patient has anemia, its [important to consider if its the] anemia driving the fatigue, or the disease, or both. Commonly, the answer is both, but its hard to tease out that answer. Aside from that, we have a lot of hypotheses about what drives fatigue. We blame cytokines, [for instance]. There may be truth to that because we do see a correlation between improvements in cytokine profiles in patients treated with JAK inhibitors and improvements in symptom burden. Fatigue improves despite patients developing some degree of anemia, so the answer is that [the reason behind fatigue] is often multifactorial.
Mascarenhas: How do you formulate your treatment plan based on symptoms?
Verstovsek: [National Comprehensive Cancer Network] guidance suggests using MPN 10 [MPN Symptom Assessment Form Total Symptom Score], a questionnaire that would cover the 10 most common symptoms. We use that questionnaire as a guide for discussion and it becomes a part of the medical record. If symptoms are affecting the patients quality of life [QOL], that is a trigger to [work with them] to improve QOL.
Mascarenhas: How are you generally classifying myelofibrosis?
Verstovsek: Many [classifications] are fixed on the grade of fibrosis in the bone marrow, [which] may have some significance on the outcome of the patients, but there are many other factors. Prognostication in terms of life expectancy does not depend solely on the degree of fibrosis. We look at patient, genetic, and chromosomal characteristics, as well as comorbidities, in deciding when to intervene. The factors would be assessment of QOL, to see whether we can control that, as well as bone marrow failure and anemia, to see whether the patient should be referred for bone marrow transplant.
Mascarenhas: Can treatment be distinguished for primary and secondary myelofibrosis, or is it broad for all subtypes?
Verstovsek: Apart from the prognostication that we discussed, I do not apply risk of dying to decide whether I should treat the patient for anemia, for [symptoms in the] spleen, or for their QOL. The trigger is recognition of poor QOL. If the spleen is big and the patient is not in pain, I would ask a few more questions. Unless you ask questions and engage with the patients, youre not going to recognize those problems. That applies to post-ET, post-PV, or primary myelofibrosis to the same degree, although [there are differences related to the] application of different therapies.
Mascarenhas: Where do clinical trials fit in terms of assessing patients for novel therapies?
Verstovsek: In a frontline setting, if platelets are above 50 109/L, you have 2 drugs: ruxolitinib [Jakafi] or fedratinib [Inrebic]. But neither is supposed to be given to patients with platelets below [that level], [which includes] about 10% to 15% of patients. [Patients with those low levels] typically have a low red blood cell count, and their spleen is not as big. This is a cytopenic patient in the frontline setting who needs something new. JAK inhibitors cover the spleen and symptoms, but they may worsen the anemia. In the frontline setting, anemia compromises the delivery of JAK inhibitors, so you need a drug for anemia. Drugs have been developed, like luspatercept [Rebozyl], to be combined with JAK inhibitors in the frontline setting. You want a combination that would enhance the JAK inhibitors, [and lead to] more spleen and symptoms control and other biological effects on the disease. Then, the durability of the response is much longer.
Mascarenhas: If you saw this patient, what would be your first-line therapy?
Verstovsek: I would not watch and wait. Age 67 [years] is still good for transplant. Further assessment with an NGS panel may push me to recommend the transplant even faster. We want to eventually cure the patient; that would be the goal. In between today and when the patient has the transplant, I treat for the symptoms and the spleen. If the anemia worsens through therapy with JAK inhibitors, you may add an anemia drug on top of it to help the patient get to their transplant in the best possible shape.
Gerds: What do you do to measure response?
Rampal: Thats a great question, and weve got to separate out what we do in clinical trials vs what we do practically speaking. It depends to some degree on what the treatment goals are. One of the treatment goals we would all agree with is to make the patient feel better, for which you can use the total symptom score. On the other hand, just talking to the patient and getting that assessment makes a difference. Lets say the patient goes to stem cell transplant; making them functionally feel better makes a difference, but [so does] spleen size. On a high level, if we have a patient who is not a transplant candidate and their spleen shrinks enough that they feel comfortable and their symptoms are improved, that [can be considered] a response.
Gerds: What are some things you look for when you consider changing therapy?
Verstovsek: I talk to the patient to understand whether there is a benefit [of the current therapy], I palpate the spleen, and I look at their weight. Then my goal would be to maintain that benefit, even if its slowly going away, by adding another agent to the JAK inhibitor. Use of pacritinib is coming as an investigational agent for patients with low platelets. That would be my first choice if I had it today. I dont have it yet, but hopefully [I will soon]. I would expand on that first line for as long as possible before I would change. In the second-line setting, we have agents that are being tested and we also have fedratinib, which is being used in the second-line setting as a JAK inhibitor. Momelotinib is [being examined in clinical trials as well], which [represents] a very interesting concept.
Rampal: One of the striking things with [momelotinib] is that [we saw] an anemia benefit, described by increases in hemoglobin and changes in theproportion of patients getting transfused. Of course, we know with JAK inhibitors that anemia is a nontarget effect. With the mechanisms of action of momelotinib hitting other pathways, we think that is probably the mechanism by which it is contributing to an anemia response. This is a profile of a JAK inhibitor, and its not one-size-fit-all. For our cytopenic patients, weve been talking about pacritinib and the hopeful approval of that drug, which clearly has a benefit for patients with cytopenia. It doesnt require dose modification based on platelet count, so that becomes an important tool in the arsenal. Then, coming to momelotinib, some patients may need something beyond just a drug for anemia. The patient who has symptomatic splenomegaly and who has anemia wont benefit from single-agent daratumumab or other related drugs. But momelotinib [may lead to] spleen size reduction and potentially anemia benefit. Were beginning to see niches for these different drugs that will greatly benefit the patients.
Verstovsek: What is the alternative pathway that the pacritinib affects in addition to the JAK pathway?
Mascarenhas: Pacritinib is interesting. There are differentiating factors [compared with] JAK inhibitors in late-stage testing. Pacritinib inhibits IRAK1, beyond JAK, and in doing so it likely affects a signaling pathway through the toll-like receptor, myosin complex, and then downstream to NF- B [nuclear factor light chain enhancer of activated B cells]. Hitting this alternative but relevant pathway in addition to JAK likely explains why this drug is less myelosuppressive [vs ruxolitinib/infigratinib]. You can give a full dose and enjoy symptom and spleen benefits with less myelosuppression. Some of the differences that well see with these JAK inhibitors are likely due to their kinome profile and some of the other targets that they hit.
In a polling question, most of the audience indicated that that they would treat this patient with pacritinib (poll question 3).
Rampal: I would not increase the dose of ruxolitinib. However, if someone is having a benefit, we must be careful. Of course, going by the FDA label, we need to attenuate, if not stop, ruxolitinib, [but] we cannot do that suddenly and risk withdrawal syndrome. In a practical sense, one could attenuate the dose of ruxolitinib and see if the platelets get betterDo they improve?and then maybe rechallenge. That is not an unreasonable option. Another clear option would be to consider switching to pacritinib, which will hopefully be approved soon. In this scenario, we have a highly symptomatic patient. They need JAK inhibition and in this circumstance, pacritinib wouldnt require dose modification due to the thrombocytopenia. It may be a fit for this patient.
Mascarenhas: From a safety standpoint, do these drugs have differences among their toxicity profiles?
Verstovsek: There are some, but they dont affect the management too much. Fedratinib has some mild [gastrointestinal] toxicities such as nausea, vomiting, and diarrhea; you can prophylactically treat them easily with medications. Pacritinib could possibly be considered first in a patient who has platelets of 81 109/L because the intensity matters. There is no need for dose adjustments. This is the area where we expect new developments, [so we can understand] what the best approach is in the frontline setting [among] those 3 drugs for patients with low platelets. When the platelets go down to 37 109/L, it is certainly not easy to manage with the currently available medications, so we welcome the new development of pacritinib.
NCCN. Clinical Practice Guidelines in Oncology. Myeloproliferative neoplasms, version 2.2021. Accessed February 10, 2022. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf
Read more:
Advances in the Treatment of Myelofibrosis - Cancer Network
- Understanding Menopause and its Symptoms | Menopause Treatment Options - Medriva - December 28th, 2023 [December 28th, 2023]
- Breast cancer survivor Jayne Pritchard talks alternative therapies over tea - MidlandToday - December 28th, 2023 [December 28th, 2023]
- 12 unusual ways Israelis are volunteering during the war - ISRAEL21c - December 28th, 2023 [December 28th, 2023]
- Complementary and alternative medicine - NHS - December 26th, 2022 [December 26th, 2022]
- Alternative Treatment (CAM) for MS: Types, Side Effects & Cost - December 26th, 2022 [December 26th, 2022]
- Complementary and alternative medicine | History & Facts - December 26th, 2022 [December 26th, 2022]
- Alternative medicine: Definition, examples, benefits, and risks - October 28th, 2022 [October 28th, 2022]
- Alternative Medicine: The Science Behind 10 Alternative Therapies - October 21st, 2022 [October 21st, 2022]
- Detoxification (alternative medicine) - Wikipedia - October 21st, 2022 [October 21st, 2022]
- Alternative Approaches to Mental Health and Wellbeing - Psychiatric Times - October 19th, 2022 [October 19th, 2022]
- New practice focuses on dental sleep medicine, providing an alternative for patients who use CPAP machines - PennLive - October 19th, 2022 [October 19th, 2022]
- Dr. Deepak Chopra Aligns with Plant-Based Therapeutics Company ProVEDA to Highlight Topical Pain Relief Solutions - Yahoo Finance - October 19th, 2022 [October 19th, 2022]
- True REST Float Spa Offers Free Floatation Therapy Session to Veterans - AccessWire - October 19th, 2022 [October 19th, 2022]
- Youve been told you need surgery for degenerative disc disease and stenosis of the spine. Now what? - Sonoran News - October 19th, 2022 [October 19th, 2022]
- Can you take Paxlovid and heart disease medications at the same time? - Medical News Today - October 15th, 2022 [October 15th, 2022]
- Kardashian fans think theyve unlocked Kourtneys secret to hiding her pregnancy after spotting key detai... - The US Sun - October 15th, 2022 [October 15th, 2022]
- Cabinet approves B5bn for 'Andaman International Health Center' - The Phuket News - October 15th, 2022 [October 15th, 2022]
- Eye health and dynamics of the modern world - The Citizen - October 15th, 2022 [October 15th, 2022]
- The Holistic Review on Occurrence, Biology, Diagnosis, and Treatment of Oral Squamous Cell Carcinoma - Cureus - October 15th, 2022 [October 15th, 2022]
- 10 Deeper Causes of Tinnitus, and How to Treat It - The Epoch Times - October 15th, 2022 [October 15th, 2022]
- Complementary and Alternative Medicine (CAM) - GoodTherapy - October 13th, 2022 [October 13th, 2022]
- India's alternative medicine industry grows, boosted by COVID-19 pandemic - CNA - October 13th, 2022 [October 13th, 2022]
- QC Kinetix (Charlotte) Offers Alternative Treatments for Knee Pain and Sports Injuries - Yahoo Finance - October 13th, 2022 [October 13th, 2022]
- Plant Extracts Market is expected to generate a revenue of USD 85.09 Billion by 2030, Globally, at 6.33% CAGR: Verified Market Research - Yahoo... - October 13th, 2022 [October 13th, 2022]
- Neuroplasticity Nonsense Is Full of Red Flags - Science Based Medicine - October 13th, 2022 [October 13th, 2022]
- Diabetics won't be made to pay for alternative medicines, Pharmac says - Stuff - October 13th, 2022 [October 13th, 2022]
- Lili Reinhart Becomes A Reiki Master: My Journey Into Reiki Healing Cant Be Simplified - IMDb - October 13th, 2022 [October 13th, 2022]
- The DRIPBaR is Coming to Clarksville, TN on Oct 16, 2022 - PR Web - October 13th, 2022 [October 13th, 2022]
- How Dr. Oz Boosted an Osteopath Who Became a Top Spreader of Covid Misinformation Mother Jones - Mother Jones - October 13th, 2022 [October 13th, 2022]
- World Arthritis Day: Arthritis and Women - Times of India - October 13th, 2022 [October 13th, 2022]
- What Is Alternative Medicine? - American Cancer Society - October 6th, 2022 [October 6th, 2022]
- Herbal medicine: Types, uses, and safety - Medical News Today - October 6th, 2022 [October 6th, 2022]
- WCI Health LLC, Your Alternative Health and Wellness Hub Will Be a Vendor and Presenter at Wonderland Miami by Microdose - StreetInsider.com - October 6th, 2022 [October 6th, 2022]
- The Viral Real - Journal #130 October 2022 - E-Flux - October 6th, 2022 [October 6th, 2022]
- Pregabalin Market to Grow by USD 153.03 Mn from 2022 to 2026, Driven by Presence of Large Patient Pool Related To Neuropathic Pain - Technavio - Yahoo... - October 6th, 2022 [October 6th, 2022]
- Woman, 37, dies after herbal supplements led to liver failure: coroner - Insider - October 6th, 2022 [October 6th, 2022]
- What Is Vitiligo? All About This Unique Skin Condition That Impacts Skin Pigmentation, and How To Treat It - Parade Magazine - October 6th, 2022 [October 6th, 2022]
- Herbalist's Resource Guide to Cannabis and Other Plants That Can Prevent Cancer - PR Web - October 6th, 2022 [October 6th, 2022]
- Tasly Pharmaceuticals to Exhibit at BioJapan 2022 -- Bio-Pharmaceutical Company to Join with Maryland-Bas - Benzinga - October 6th, 2022 [October 6th, 2022]
- "Sh*t, I just want to get better. Thats what pushed me to do it, and it worked well" Chauncey Billups and other NBA stars on acupuncture -... - October 6th, 2022 [October 6th, 2022]
- People Science and Symbiome Partner to study the microbiome in the real world - Benzinga - October 6th, 2022 [October 6th, 2022]
- Bob Newhart Proves 93 Is the New 39 - Eat This, Not That - September 29th, 2022 [September 29th, 2022]
- Medical cannabis could be better alternative to opioids in managing pain - The Tribune India - September 29th, 2022 [September 29th, 2022]
- Woman killed by herbal remedies she took to treat arthritis - Evening Standard - September 29th, 2022 [September 29th, 2022]
- Get To Know The Best Natural Adderall Alternatives - Over The Counter and Non Prescription - Outlook India - September 29th, 2022 [September 29th, 2022]
- King Charles III Has a History of Promoting 'Quackery' Alternative Medicine - Newsweek - September 9th, 2022 [September 9th, 2022]
- Remedy Place: The Fashionable Social Wellness Club Where You Can Bring All Your Friends - Vogue - September 9th, 2022 [September 9th, 2022]
- Thailand heightens its healthcare hub ambition with integrative medicine - PR Newswire UK - September 9th, 2022 [September 9th, 2022]
- How bogus cancer treatments prey on the most vulnerable - Coda Story - September 9th, 2022 [September 9th, 2022]
- Management of Chronic Migraine in Children and Adolescents | PHMT - Dove Medical Press - September 9th, 2022 [September 9th, 2022]
- Mouth Taping: Is It Safe? - Health Essentials - September 9th, 2022 [September 9th, 2022]
- Queen Elizabeth: Seven things you need to know about the Queens passing - Toronto Star - September 9th, 2022 [September 9th, 2022]
- Building an Alternative Medical Economy in Response to 'Tyranny': Telehealth CEO - The Epoch Times - August 30th, 2022 [August 30th, 2022]
- Sesame oil: Nutrition, benefits, and more - Medical News Today - August 30th, 2022 [August 30th, 2022]
- Regenerative Medicine: An alternative to surgery and pills | Loop Cayman Islands - Loop News Cayman - August 30th, 2022 [August 30th, 2022]
- Find Euphoria: the luxury Greek spa retreat to visit now - Tatler - August 30th, 2022 [August 30th, 2022]
- What Is Synthetic Urine & How Does It Help To Pass A Drug Test? - The Island Now - August 30th, 2022 [August 30th, 2022]
- The science behind the healthtech startup must be understood well - Express Healthcare - August 30th, 2022 [August 30th, 2022]
- Best-in-class second-line HIV treatment rolls out in Zambia and Nigeria - Clinton Health Access Initiative - August 30th, 2022 [August 30th, 2022]
- Therapeutic effect of HFNC and NIV in patients with AECOPD | COPD - Dove Medical Press - August 30th, 2022 [August 30th, 2022]
- Five years after Kymriah: Ensuring the next cell and gene therapies reach patients - STAT - August 30th, 2022 [August 30th, 2022]
- Meet these renowned healthcare professionals who assist us in leading healthier lives - Oneindia - August 30th, 2022 [August 30th, 2022]
- Diet and Vitiligo: The Story So Far - Cureus - August 29th, 2022 [August 29th, 2022]
- Fatphobia Sucks, Especially If You're Trying to Have a Baby - VICE - August 29th, 2022 [August 29th, 2022]
- Orthomolecular Medicine, A Predictive Tool - Nation World News - August 29th, 2022 [August 29th, 2022]
- COVID-19 vaccines and the Nuremberg Code - Science Based Medicine - August 29th, 2022 [August 29th, 2022]
- Bolstering the Blood-CNS Barrier Could Lead to New Treatment Approach for Multiple Sclerosis - University of Utah Health Care - August 29th, 2022 [August 29th, 2022]
- Lockdowns Postponed the Inevitable. Is That a Bad Thing? - Science Based Medicine - August 29th, 2022 [August 29th, 2022]
- The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review - Cureus - August 27th, 2022 [August 27th, 2022]
- Ayurveda As Alternative Medicine: Research And Development To Be Taken Ahead By Heal In India - Entrepreneur - August 27th, 2022 [August 27th, 2022]
- French Doctolib platform accused of 'promoting alternative medicine' - The Connexion - August 27th, 2022 [August 27th, 2022]
- Chronic Fatigue Syndrome: Best Ways for Treating This Condition - Healthline - August 27th, 2022 [August 27th, 2022]
- Ellen White reveals "traumatic" incident that played huge role in her retirement - GIVEMESPORT - August 27th, 2022 [August 27th, 2022]
- Curcumin and Non-Hodgkin's Lymphoma: Does It Help? - Healthline - August 27th, 2022 [August 27th, 2022]
- In Denial: When Patients Don't Want to Believe They Have Cancer - Medscape - August 27th, 2022 [August 27th, 2022]
- Piotr Szyhalski depicts living through COVID-19 and other extreme historical phenomena - MinnPost - August 27th, 2022 [August 27th, 2022]
- Researchers identify chemo alternative for targeted treatment of leukemia patients - Devdiscourse - August 27th, 2022 [August 27th, 2022]
- India Can Show The World The Right Path For Medical Pluralism - News18 - August 27th, 2022 [August 27th, 2022]
- Complementary and Integrative Medicine - Reeve Foundation - Christopher Reeve Foundation - August 23rd, 2022 [August 23rd, 2022]
- Back pain: Exploring alternative treatments - Health - Life & Style - Ahram Online - August 23rd, 2022 [August 23rd, 2022]